TAK vs TEVA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TEVA Captures Institutional Edge (3โ1 Pillars ยท 4โ6 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while TAK counters with relative strength in Valuation. Fundamentally, TAK trades at 12.7x Forward P/E with 16.6% operating margin (+6.7% YoY revenue) versus TEVA at 14.2x Forward P/E and 19.9% operating margin (-1.9% YoY). In options structure, TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro) against TEVA sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | TAK | TEVA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $67.5B | $51.1B | Larger Scale | TAK |
| Trailing P/E Ratio Valuation | N/M | 101.8x | Lower Multiple | TEVA |
| Forward P/E Ratio Valuation | 12.7x | 14.2x | Lower Multiple | TAK |
| Revenue Growth (YoY) Growth | +6.7% | -1.9% | Higher Growth | TAK |
| Operating Margin (TTM) Profitability | 16.6% | 19.9% | Higher Margin | TEVA |
| Net Profit Margin Profitability | 0.9% | 2.9% | Higher Margin | TEVA |
| Return on Equity (ROE) Capital Efficiency | 0.6% | 6.7% | Higher ROE | TEVA |
| 52-Week Range Position Momentum | 97% ($14โ$22) | 92% ($24โ$45) | Stronger Trend | TAK |
| Beta / 30D Volatility Risk Regime | -0.02ฮฒ ยท 22% Vol | 0.51ฮฒ ยท 29% Vol | Lower Realized Risk | TAK |
| Unified Institutional Score Composite Signal | 47.7 / 100 (HOLD) | 29.8 / 100 (SELL) | Higher Composite | TAK |